Clinical Trial Update: A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating TY-9591 in combination with chemotherapy as first-line treatment for EGFR-mutated non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TY-9591 (TY-9591)

Snippet

Sponsor: TYK Medicines, Inc | Conditions: NSCLC | Phase 2 | Status: NOT_YET_RECRUITING